Pfizer has announced plans to lower its Xeljanz (tofacitinib) trial dosing from 10mg twice-daily to 5mg twice-daily, after pulmonary embolisms were found to be more frequent among patients treated with the higher dose.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.